Lilly Diabetes International

Promoting a more compassionate approach and reducing stigma can break down barriers to effective management of chronic metabolic diseases and open the door to better health.

Exploring the links between #Cardiometabolic diseases is key to advancing cardiometabolic care. An overall understanding of the interconnected metabolic and multi-organ processes may help move cardiometabolic care beyond traditional methods.

Following #ATTD2026, Prof. Tofé explores a critical question in #Type2Diabetes: How may early, intensive management change clinical outcomes? Watch this video where he discusses the role of early intervention in preserving beta-cell function and influencing disease progression.

Goodbye #ATTD2026! Thank you to all attendees, speakers, partners, and visitors to our booth for making this year’s event a success. We enjoyed connecting, learning, and sharing in the conversations shaping the future of #DiabetesCare.

At Lilly, we are dedicated to improving people’s lives by advancing understanding of #Cardiometabolic diseases and the connections between them, bringing this commitment to #ATTD2026. Follow us for more insights.

Look out for our campaign at train stations across Barcelona during #ATTD2026! You might spot Lilly’s message highlighting our effort to help advance #DiabetesCare. Health takes all of us!

Let’s celebrate innovation in #Type2Diabetes care! The ATTD Breakthrough Outcomes Award, supported by Lilly, recognizes outstanding achievements in clinical practice for people with T2D. Join us at the #ATTD2026 Closing Ceremony.

At Lilly, we believe progress happens when scientific advances make people’s lives better. A future where interconnected #Cardiometabolic diseases are globally understood can help shift attitudes and make healthcare more accessible, connected, and human. Join us at #ATTD2026.

Individualized, early, and intensive #DiabetesCare — that’s the direction set by the 2022 ADA/EASD consensus report. Find us at #ATTD2026 to talk more about why early intervention matters.

Our legacy in #Cardiometabolic care drives us to meet today’s evolving healthcare needs—supporting people living with diabetes and obesity through improved access and equity. At #ATTD2026, we continue advancing cardiometabolic, from early risk to advanced disease.

Join the Lilly symposium at #ATTD2026. We will be talking about translating science into outcomes, in the context of the progressive nature of #Type2Diabetes.

What if one health check could help identify cardiometabolic risk before symptoms appear? Visit the ATTD Screening at #ATTD2026, supported by Lilly, offering professional medical assessments designed to advance early risk identification and informed action. See you there!

As the global diabetes community gathers for #ATTD2026, Lilly is sharing a message across Barcelona (BCN) about the role we all play in helping advance #DiabetesCare. Keep an eye out! You might even spot it at the airport welcoming attendees to the congress.

At #ATTD2026, we highlight Lilly’s commitment to advancing cardiometabolic health. Half a century ago, our work in metabolic diseases helped open new pathways in cardiovascular science. That same passion continues today, driving innovation in diabetes across the disease spectrum.

At #ATTD2026, we highlight Lilly’s role in helping advance #Cardiometabolic care. For more than a century, Lilly has been helping optimize #DiabetesCare. Today, we are as dedicated as ever to helping transform cardiometabolic care for people living with diabetes and obesity.

#Cardiometabolic diseases, such as #Type2Diabetes and #Obesity, coupled with CV complications, share risk factors that can often be overlooked. Follow us for more on the science behind connected cardiometabolic care.

Welcome to Barcelona! Join us during #ATTD2026, where the global community meets to exchange perspectives on #DiabetesCare. Follow us to stay connected.

What’s the top area you’re planning to explore at ATTD 2026?

The understanding of #Cardiometabolic diseases, such as #Type2Diabetes and #Obesity, coupled with CV complications, is advancing as new risk factors and mechanisms are identified.¹ Follow us as we explore the evolving science behind cardiometabolic care.

As an active supporter and contributor to advancing #DiabetesCare, we are looking forward to being part of #ATTD2026, in Barcelona, Spain, from 11–14 March 2026. Follow us to stay updated.